Preliminary results from a 15-month open-label extension (OLE) study investigating RG6042 huntingtin protein (HTT) antisense oligonucleotide (ASO) in adults with manifest Huntington’s disease (HD)

Feb 27, 2020 by [Schobel SA]

Long-term safety, tolerability and biomarker effects of tominersen (most recently known as RG6042) were evaluated in participants of the 15-month open-label extension of the Phase I/IIa study. Results of this preliminary 15-month analysis will be presented.

Current View

Receive this presentation and more content via email